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Introduction

Demographics

Results
• As of July 2022, 31 patients (58.5%) were alive without disease, 18
(34.0%) alive with disease, 3 (5.7%) dead of unreported causes, and
1 (1.8%) dead of vulvar cancer.

• Vulvar cancer is a rare malignancy, accounting for
less than 5% of gynecologic cancers.
• Vulvar dysplasia is a non-malignant series of
changes in the vulva that has the potential to
progress to vulvar cancer.

• The average age of patients with advanced vulvar cancer (62.4
years) was greater than those with early-stage vulvar cancer (56.2
years) or dysplasia (51.2 years), though this was not significant
(p=.26).

• Risk factors for advanced vulvar cancer or
dysplasia include older age, human papillomavirus
(HPV), tobacco use, and immunodeficiency.1

• While insignificant, there seemed to be a higher rate of HPV in
patients with vulvar cancer (p=1.0). While patients with early-stage
vulvar cancer tended to show higher rates of HPV than patients with
late-stage vulvar cancer, this was also not significant (p=.70).

• These patients tend to present with comorbidities
including cardiovascular disease, pulmonary
disease, and diabetes, which complicates treatment
and contributes to less favorable outcomes.2

• The average Charlson Comorbidity Index (CCI) score of vulvar
cancer patients was significantly greater than patients with vulvar
dysplasia (4.89 vs. 2.44, p<.05).

• It has been suggested that patients with HPVrelated vulvar cancer or dysplasia are likely to have
died from a comorbidity rather than from vulvar
disease.3

• Average CCI score was significantly greater for patients with latestage vulvar cancer than for patients with early-stage vulvar cancer
(7.78 vs 4.06, p=.01). Of the studied comorbidities, pulmonary
disease such as COPD or asthma was most strongly associated with
vulvar cancer (p=.04).

• It seems that patients with vulvar disease unrelated
to HPV often present with and pass from more
aggressive forms of their disease.3

• While insignificant, patients with early-stage vulvar cancer tended
to have the highest average overall survival (21.9 months), followed
by patients with vulvar dysplasia (15.2 months) and those with latestage vulvar cancer (14.6 months).

• The objective of this study was to describe the
causes of death in patients diagnosed with vulvar
cancer or dysplasia in Louisiana.

Methods

Table 1: Patient Demographic Overview, by Disease Stage
*Non-African American patients included patients of the following
races, in order of decreasing incidence: White/Caucasian, Asian, Other
Note: There were 8 patients whose vulvar cancer were not yet staged; thus,
they are excluded from this table.

• Patients with HPV-related vulvar cancer also tended to have a
higher overall survival (23.9 months) compared to patients with
vulvar disease unrelated to HPV (12.8 months), though this was also
not significant (p=.07).

Patient Outcomes

• Retrospective analysis of 53 patients diagnosed with
vulvar cancer or dysplasia between 2013 and 2022
was performed.
• Patients were primarily seen by gynecologic
oncologists at a mix of academic and community
hospitals in Louisiana.
• Patient data was abstracted for demographic and
clinical variables including tobacco history, HPV
status, comorbidities, and disease status.
• Categorical distributions across groups were
analyzed using Fisher exact tests and two-sample ttests, and continuous covariates were summarized
using a Wilcoxon rank-sum test.

• Of the 35 patients with vulvar cancer and 18 patients with vulvar
dysplasia, 31 patients (58.5%) were alive without disease, 18 (34.0%)
alive with disease, 3 (5.7%) dead of unreported causes, and 1 (1.8%)
dead of vulvar cancer. (Figure 1)

Conclusions
Our study was limited by size, but in our vulvar cancer and dysplasia
population, a majority died from conditions other than vulvar
cancer. Those with advanced vulvar disease were significantly older,
comorbid, and more likely to have pulmonary disease.
We were pleased to see so few deaths within our patient group. This
illustrates the impact of prevention, healthcare access, and
optimization opportunities during vulvar cancer treatment and
surveillance with gynecologic oncology. The limitation in available
data presents us with an opportunity for additional work in the
future to identify cause of death in patients with vulvar disease by
expanding our sample size to increase the study’s power.
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